COMPANY

Oncotherapy Solutions

Keywords: oncology solid tumors triple-negative breast cancer

Location: Seattle, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $400K (SBIR Phase I 1R43CA306418-01A1, new, notice Sep 17, 2026). NIH RePORTER 1R43CA306418-01A1 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R43CA306418-01A1
  Organization: ONCOTHERAPY SOLUTIONS, LLC; City/State: Seattle, WA; Project number: 1R43CA306418-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Stable, highly potent and safe lead peptide drug conjugate for the treatment of triple-negative breast cancer.; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 17, 2026 Grant Government grant — SBIR: $400,000 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $400,000 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗

Annual award amounts. Total $300K.

May 18, 2018 NIH award 1R43CA221464-01A1 FY2018: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI LAMHARZI, NAJIB; recipient as written: ONCOTHERAPY SOLUTIONS, LLC, Seattle, WA. Novel peptide drug conjugates for the source ↗